Thomas M. Wheeler

Thomas M. Wheeler's AcademicInfluence.com Rankings

Thomas M. Wheeler

Medical

#2264

World Rank

#2673

Historical Rank

Oncology

#130

World Rank

#134

Historical Rank

medical Degrees

Thomas M. Wheeler

Biology

#8931

World Rank

#12075

Historical Rank

Pathology

#118

World Rank

#234

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Thomas M. Wheeler's Degrees

Doctorate Medicine Harvard University
PhD Molecular Biology Stanford University

Why Is Thomas M. Wheeler Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thomas M. Wheeler's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006) (3857)
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (3403)
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder (1998) (1501)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2007) (1419)
Radical prostatectomy versus observation for localized prostate cancer. (2012) (1359)
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. (1998) (1269)
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. (2002) (987)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) (760)
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. (1999) (730)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (668)
Prognostic significance of positive surgical margins in radical prostatectomy specimens. (1995) (537)
Factors predicting recovery of erections after radical prostatectomy. (2000) (474)
Follow‐up of Prostatectomy versus Observation for Early Prostate Cancer (2017) (430)
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. (2003) (364)
Elevated expression of caveolin is associated with prostate and breast cancer. (1998) (360)
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. (2003) (337)
CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer (2007) (334)
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. (2005) (331)
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. (2007) (325)
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. (2003) (320)
Do Adenocarcinomas of the Prostate With Gleason Score (GS)⩽6 Have the Potential to Metastasize to Lymph Nodes? (2012) (312)
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. (1999) (311)
Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. (1999) (307)
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins (2011) (296)
Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. (2000) (272)
The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. (1989) (271)
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. (2001) (269)
Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. (1995) (257)
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. (2004) (246)
Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. (2009) (246)
Accuracy of fine-needle aspiration of thyroid. (2001) (243)
Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. (1998) (242)
Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. (2001) (241)
Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. (1992) (241)
A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. (1991) (239)
Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma (1997) (238)
The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. (1994) (237)
The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. (2003) (237)
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? (1994) (236)
Protocol for the examination of specimens from patients with carcinoma of the prostate gland. (2009) (235)
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens (2005) (233)
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume (2010) (226)
Age-Related DNA Methylation Changes in Normal Human Prostate Tissues (2007) (226)
15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. (2001) (225)
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. (2001) (225)
An analysis of men with clinically localized prostate cancer who deferred definitive therapy. (2004) (222)
Cancer-Related Axonogenesis and Neurogenesis in Prostate Cancer (2008) (220)
High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and Non-Neoplastic Prostate Tissues Are Strong Predictors of Biochemical Recurrence (2004) (216)
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. (2003) (212)
The Mechanisms and Prognostic Significance of Seminal Vesicle Involvement by Prostate Cancer (1993) (212)
Growth and Survival Mechanisms Associated with Perineural Invasion in Prostate Cancer (2004) (210)
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease (2011) (206)
High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in Prostate: Cancer Patients Treated With Radical Prostatectomy (2004) (206)
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. (2002) (202)
Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. (2001) (201)
Prognostic significance of location of positive margins in radical prostatectomy specimens. (2007) (200)
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. (2007) (200)
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. (1996) (199)
Heterogeneity of prostate cancer in radical prostatectomy specimens. (1994) (194)
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. (2013) (189)
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling (2011) (188)
A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. (2000) (184)
Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression (2004) (177)
"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. (2000) (176)
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma (2020) (174)
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. (1996) (164)
Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. (2011) (161)
Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. (1994) (155)
Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. (2002) (153)
Is tumor volume an independent prognostic factor in clinically localized prostate cancer? (2004) (153)
Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia (1995) (150)
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. (2006) (148)
A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. (2003) (140)
Thymic Carcinoma A Clinicopathologic Study of 13 Cases (1990) (139)
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes (2011) (138)
The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. (1986) (136)
Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens (2008) (135)
Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens (2005) (135)
Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. (1997) (135)
Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. (1988) (132)
Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. (1999) (132)
Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. (2004) (131)
Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors (2003) (130)
Evaluating localized prostate cancer and identifying candidates for focal therapy. (2008) (129)
Association of p53 mutations with metastatic prostate cancer. (1995) (126)
The emerging role of the PI3-K-Akt pathway in prostate cancer progression (2005) (124)
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? (1997) (124)
A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. (2007) (121)
Predictors of prostate cancer after initial negative systematic 12 core biopsy. (2004) (119)
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. (2001) (119)
Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. (2001) (116)
Improved prediction of prostate cancer recurrence through systems pathology. (2007) (116)
Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. (2001) (116)
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. (2004) (115)
The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of D (2014) (113)
Age-related radical-induced DNA damage is linked to prostate cancer. (2001) (113)
Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. (2007) (113)
Metabolomic signatures of aggressive prostate cancer (2013) (113)
Workgroup 2: Staging and reporting of prostate cancer‐‐Sampling of the radical prostatectomy specimen (1996) (108)
Anatomic considerations in carcinoma of the prostate. (1989) (107)
Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. (2006) (106)
In situ end-labeling of human testicular tissue demonstrates increased apoptosis in conditions of abnormal spermatogenesis. (1997) (105)
Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. (2008) (103)
Understanding the pathological features of focality, grade and tumour volume of early‐stage prostate cancer as a foundation for parenchyma‐sparing prostate cancer therapies: active surveillance and focal targeted therapy (2011) (101)
Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. (1996) (100)
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. (2001) (99)
DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. (2009) (99)
Differential expression of nuclear retinoid receptors in normal and malignant prostates. (2000) (99)
Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. (2002) (97)
Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. (2003) (97)
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma (2001) (94)
Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia (2000) (93)
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. (2001) (92)
Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. (1997) (91)
Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. (1988) (91)
Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. (1994) (91)
Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. (1998) (91)
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. (2003) (90)
Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy: An Interobserver Study among Experts in Genitourinary Pathology (2008) (90)
Primary Gleason Pattern as a Predictor of Disease Progression in Gleason Score 7 Prostate Cancer: A Multivariate Analysis of 823 Men Treated With Radical Prostatectomy (2001) (90)
The frequency of apoptosis correlates with the prognosis of gleason grade 3 adenocarcinoma of the prostate (1995) (88)
Pathologic basis of the sonographic appearance of the normal and malignant prostate. (1989) (87)
DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. (1991) (87)
Lymphovascular invasion as a predictor of disease progression in prostate cancer. (2000) (87)
Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. (2007) (87)
Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. (2006) (86)
The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. (1991) (85)
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. (2010) (84)
Staging of prostate cancer. Value of ultrasonography. (1989) (83)
Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). (1997) (80)
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. (2001) (80)
Cytokeratins 7 and 20 Immunoreactivity in Chromophobe Renal Cell Carcinomas and Renal Oncocytomas (2002) (77)
Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. (2000) (76)
1574: Is Focal Therapy Reasonable in Patients with Early Stage Prostate Cancer (CAP) - an Analysis of Radical Prostatectomy (RP) Specimens (2006) (76)
Expression of neutral amino acid transporter ASCT2 in human prostate. (2003) (76)
Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. (2003) (75)
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. (2004) (72)
Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort (2006) (71)
Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. (2000) (71)
The role of caveolin-1 in androgen insensitive prostate cancer. (2002) (70)
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. (2003) (70)
Assessment of the biologic markers p53, ki‐67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery (1998) (69)
Apoptotic frequency is increased in spermatogenic maturation arrest and hypospermatogenic states. (1997) (69)
Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level (1995) (67)
Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. (2002) (67)
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. (1999) (66)
Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. (1996) (65)
Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. (2007) (65)
Pim‐2 upregulation: Biological implications associated with disease progression and perinueral invasion in prostate cancer (2005) (65)
Bilateral nerve graft during radical retropubic prostatectomy: 1-year followup. (2001) (64)
Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. (1991) (64)
Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. (1999) (63)
Side Effects and Ways to Avoid Them (1982) (63)
Radical prostatectomy for carcinoma of the prostate (2004) (61)
Elevated caveolin-1 levels in African-American versus white-American prostate cancer. (2000) (61)
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. (1998) (60)
IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. (2003) (59)
Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. (2004) (59)
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. (2006) (58)
Immunohistochemical and ultrastructural study of rhabdosphincter component of the prostatic capsule. (1997) (58)
Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. (2006) (57)
Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder (2001) (57)
Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. (2003) (57)
Testicular metastasis as the first manifestation of colon carcinoma. (1988) (56)
Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. (2011) (56)
Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. (1995) (55)
Incidence, Location, and Significance of Periprostatic and Periseminal Vesicle Lymph Nodes in Prostate Cancer (2001) (54)
A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. (2005) (54)
Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. (2003) (54)
Cancer‐specific survival and predictors of prostate‐specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy (2006) (53)
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. (2013) (51)
Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. (1994) (51)
Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives (2005) (49)
Neural cell adhesion molecule is upregulated in nerves with prostate cancer invasion. (2003) (48)
Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. (2008) (48)
Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. (2004) (47)
Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. (1998) (47)
Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney). (2008) (47)
Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. (2004) (46)
Neuroepithelial interactions in prostate cancer are enhanced in the presence ofprostatic stroma. (2003) (45)
Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index (1996) (45)
Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. (1999) (45)
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. (2002) (44)
Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. (2003) (43)
Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis. (2014) (43)
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist (2014) (42)
Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. (2004) (41)
Verumontanum Mucosal Gland Hyperplasia (1995) (41)
Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. (2000) (41)
Cytopathic effect of in situ gene therapy in prostate cancer. (2000) (40)
Predictors of Extracapsular Extension and Its Radial Distance in Prostate Cancer: Implications for Prostate IMRT, Brachytherapy, and Surgery (2003) (40)
Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. (2019) (39)
Granulomatous infections complicating hairy cell leukemia (1982) (39)
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. (2004) (39)
Prognostic Value of Akt-1 in Human Prostate Cancer: A Computerized Quantitative Assessment with Quantum Dot Technology (2009) (39)
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. (2002) (38)
Anatomy of the prostate gland and surgical pathology of prostate cancer (2008) (38)
Miotics: side effects and ways to avoid them. (1982) (37)
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. (2004) (37)
Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer. (2009) (37)
Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature. (2008) (36)
Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. (2019) (36)
Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. (2000) (36)
Ultrasonic detection of non-palpable seminal vesicle invasion: a clinicopathological study. (1993) (36)
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. (1999) (36)
Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer. (1994) (35)
Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate. (2006) (35)
Intraductal carcinoma of the prostate: Precursor or aggressive phenotype of prostate cancer? (2013) (35)
Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting (2013) (34)
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma (2018) (34)
Prostatic biopsy after irradiation therapy for prostatic cancer. (1985) (33)
Intravascular papillary endothelial hyperplasia of the orbit and ocular adnexa. A report of five cases. (1983) (33)
Biological correlates of p27 compartmental expression in prostate cancer. (2006) (33)
Reporting guidelines for clinical laboratory reports in surgical pathology. (2008) (33)
Is year of radical prostatectomy a predictor of outcome in prostate cancer? (2004) (32)
Unusual hyperechoic appearance of prostate cancer on transrectal ultrasonography. (1992) (31)
Frozen section of thyroid and parathyroid specimens. (2005) (31)
Five year follow-up after radical prostatectomy for localized prostate cancer--a study of the impact of different tumor variables on progression. (1994) (31)
Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. (2007) (31)
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. (2005) (31)
Reduced Infiltration of Class A Scavenger Receptor Positive Antigen-Presenting Cells Is Associated with Prostate Cancer Progression (2004) (30)
Myospherulosis: a preventable iatrogenic nasal and paranasal entity. (1980) (30)
In Situ End-Labeling of Human Testicular Tissue Demonstrates Increased Apoptosis in Conditions of Abnormal Spermatogenesis (1998) (30)
Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. (2003) (29)
Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible? (2003) (29)
The striated urethral sphincter: muscle fibre types and distribution in the prostatic capsule. (1997) (28)
GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy (2011) (28)
Paraganglia of the Prostate: Location, Frequency, and Differentiation from Prostatic Adenocarcinoma (1994) (28)
Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. (1994) (28)
Biological correlates of prostate cancer perineural invasion diameter. (2014) (27)
Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. (2008) (27)
Bortezomib-Mediated Inhibition of Steroid Receptor Coactivator-3 Degradation Leads to Activated Akt (2008) (27)
The pathophysiology of neurofibromatosis. II. Angiosarcoma as a complication. (1984) (26)
Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages (2016) (26)
Distribution and significance of microcalcifications in the neoplastic and nonneoplastic prostate. (1998) (25)
Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? (2002) (25)
Elevated Skp 2 Protein Expression in Human Prostate Cancer : Association with Loss of the Cyclin-dependent Kinase Inhibitor p 27 and PTEN and with Reduced Recurrence-free Survival 1 (2002) (24)
Protein expression profiling of endometriosis: validation of 2-mm tissue microarrays. (2004) (23)
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. (2020) (23)
Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting (2019) (23)
The association of selected pathological features with prostate cancer in a single-needle biopsy accession. (1998) (23)
Postatrophic Hyperplasia of the Prostate (1999) (23)
The significance of intraluminal prostatic crystalloids in benign needle biopsies. (1998) (23)
Myospherulosis--further observations. (1980) (22)
Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. (2019) (22)
Ethnic and racial differences in prostate stromal estrogen receptor α (2005) (21)
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer (2013) (21)
ISUP Consensus Definition of Cribriform Pattern Prostate Cancer (2021) (20)
Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma. (1995) (20)
Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). (2019) (20)
Transrectal ultrasonography in stage A prostate cancer: detection of residual tumor after transurethral resection of prostate. (1991) (19)
RESULTS OF THE CANCER-RESEARCH CAMPAIGN ADJUVANT TRIAL FOR PERIOPERATIVE CYCLOPHOSPHAMIDE AND LONG-TERM TAMOXIFEN IN EARLY BREAST-CANCER REPORTED AT THE 10TH YEAR OF FOLLOW-UP (1992) (19)
Recurrent hypercalcemia due to ectopic production of parathyroid hormone-related protein and intact parathyroid hormone in a single patient with multiple malignancies. (2004) (18)
Leu‐7 immunoreactivity in cytologic specimens of thyroid lesions, with emphasis on follicular neoplasms (1995) (17)
Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. (2015) (17)
Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy. (1992) (16)
Granular necrosis: a distinctive form of cell death in malignant tumours. (2020) (15)
Thyroid cancer presenting as a hot thyroid nodule: report of a case and review of the literature. (1988) (15)
Ultrasonographic changes in the normal and malignant prostate after definitive radiotherapy. (1989) (14)
Moving Beyond Gleason Scoring. (2019) (13)
Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice (2010) (13)
The sonographic appearance of irradiated prostate cancer. (1991) (12)
Expanding the Therapeutic Index of Radiation Therapy by Combining In Situ Gene Therapy in the Treatment of Prostate Cancer (2006) (12)
Tamm‐Horsfall Protein in Bladder Tissue: Morphologic Spectrum and Clinical Significance (1994) (12)
Verumontanum mucosal gland hyperplasia is associated with atypical adenomatous hyperplasia of the prostate. (1997) (12)
Visceral pericardial hemangioma: unusual location for a rare cardiac tumor. (2005) (11)
Pelvic lymph node histiocytosis mimicking metastatic prostatic adenocarcinoma: association with hip prostheses. (1995) (11)
Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. (1996) (10)
Sural Nerve Interposition Grafting during Radical Prostatectomy. (2002) (10)
Morphometric analysis of calcification and fibrous layer thickness in carotid endarterectomy tissues (2016) (9)
Infertility in the Male: Testicular biopsy in male infertility evaluation (2009) (9)
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. (2017) (9)
Radical Prostatectomy: Assessment of Morbidity and Pathologic Findings (1987) (9)
Taking DNA from the dead (2010) (8)
Active surveillance for prostate cancer: the role of the pathologist. (2015) (8)
Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. (2021) (7)
Pseudolumen Size and Perimeter in Prostate Cancer: Correlation with Patient Outcome (2011) (7)
Significance of Hypoechoic Lesions in the Irradiated Prostate (1989) (7)
The sensitivity of detection of asbestos bodies in sputa and bronchial washings. (1988) (7)
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. (2020) (7)
Angioimmunoblastic lymphadenopathy with hypogammaglobulinemia. Possible role of monocyte suppression. (1982) (7)
Impalpable prostate cancer: clinicopathological features. (1996) (6)
Clinical relevance of the individual prostate cancer focus. (1994) (6)
Significance of the craniocaudal distribution of cancer in radical prostatectomy specimens (2007) (6)
Intensity-modulated radiation therapy (IMRT) for localized prostate cancer: A comparison of peacock conformal treatment volumes and pathologic radical prostatectomy specimens (1998) (6)
Ultrasonic Determination of Extracapsular Extension: A Clinicopathologic Study (1987) (6)
RISK ASSESSMENT OF T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER USING P53 IMMUNOHISTOCHEMISTRY AND PATHOLOGIC SUBSTAGING (1999) (6)
Atypical Small Acinar Proliferation (2013) (6)
Intraductal carcinoma of the prostate is not a diagnostic entity (2020) (5)
1374: The Sensitivity of Transurethral Biopsy for Detecting Prostatic Involvement by Transitional Cell Carcinoma in Patients Undergoing Radical Cystoprostatectomy (2005) (5)
Improved prediction of PSA recurrence through systems pathology. (2004) (5)
An Innovative Interactive Modeling Tool to Analyze Scenario-Based Physician Workforce Supply and Demand (2015) (5)
A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging. (2020) (5)
Sonographic monitoring of prostate cancer after definitive radiotherapy. (1992) (5)
Whole Organ Mapping of Radical Prostatectomy Specimens (1987) (5)
Is there really a difference between peripheral zone and transition zone prostate cancer (1995) (4)
THE INFLUENCE OF PATHOLOGICAL PARAMETERS OF POSITIVE SURGICAL MARGINS ON PROGNOSIS IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY (1999) (4)
Expulsive choroidal hemorrhage in the glaucoma patient. (1987) (4)
Successful management of Histoplasma capsulatum infection of an abdominal aortic aneurysm. (1986) (4)
Phase I/II trial evaluating combined radiotherapy and in-situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-an interim report on PSA response and biopsy data (2002) (3)
Diagnosis of benign and malignant thyroid disease in the East Kazakhstan Region of the Republic of Kazakhstan (1998) (3)
[The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification]. (2002) (3)
Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy (2019) (3)
Tamm-Horsfall protein in bladder tissue (1994) (3)
Cytokine Gene Therapy for Genitourinary Cancer (2007) (2)
Aspiration fluid cytology during single operator cholangioscopy with targeted biopsy to improves the diagnostic yield in indeterminate biliary strictures (2021) (2)
Successful management of infection of an abdominal aortic aneurysm (1986) (2)
Desquamating apoptotic variant of high-grade prostatic intraepithelial neoplasia: a possible precursor of intraductal prostatic carcinoma. (2011) (2)
Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
PSA nadir and 24 month biopsy interim analysis of AdV-tk/Valacyclovir gene therapy in combination with radiotherapy vs radiotherapy alone for prostate cancer. (2004) (2)
Intratesticular Adenomatoid Tumor Radiographically Mimicking A Primary Testicular Malignancy (2004) (2)
Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). (2009) (2)
PREOPERATIVE PLASMA IGF-1 LEVELS DO NOT CORRELATE WITH FINAL PATHOLOGIC STAGE OR PROGRESSION IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY (1999) (1)
REACTIVE STROMA GRADE 3 IN PROSTATECTOMY SPECIMENS: A CONTINUOUS AND INDEPENDENT NOVEL BIOMARKER FOR BIOCHEMICAL RECURRENCE-FREE SURVIVAL AND CANCER RELATED DEATH IN PROSTATE CANCER (2009) (1)
RADICAL PROSTATECTOMY VERSUS OBSERVATION FOR EARLY PROSTATE CANCER: FOLLOW‐UP RESULTS OF THE PROSTATE CANCER INTERVENTION VERSUS OBSERVATION TRIAL (PIVOT): PNFLBA‐11 (2017) (1)
Zone Prostate Tissue Elevated in Prostate Cancer Compared with Benign Transition A Precursor Form of Prostate-specific Antigen Is More Highly (2000) (1)
1433: Association of Blood Levels of Components of the Urokinase System of Plasminogen Activation with Prostate Cancer Presence, Invasion, Progression, and Metastasis (2007) (1)
Phase I trial of NY-ESO-1/LAGE1 peptide vaccine for metastatic castration resistant prostate cancer (mCRPC). (2012) (1)
Book ReviewBiopsy Interpretation of the Prostate, J.I. Epstein, G. Netto, 4th ed., Lippincott Williams and Wilkins, Philadelphia (2007), 368 pages (2009) (1)
800: Presence of Peripheral Zone Cancer at the Apical Shave is Important Prognostic Factor (2004) (1)
Predicting prostate-cancer-specific death: Is it in the cancer? (2010) (1)
RACIAL DIFFERENCES IN THE SIZE AND GRADE OF PROSTATE CANCER TUMOR FOCI (1999) (1)
Abdominal Wall Endometriosis as Endometrioma-Cutaneous Fistula: A Case Report (2014) (1)
HIGH LEVEL OF TOTAL AKT-1 PREDICTS HIGH-RISK OF BIOCHEMICAL RECURRENCE AND PROSTATE CANCER SPECIFIC DEATH (2009) (1)
Postoperative N omogram f or D isease R ecurrence After R adical P rostatectomy f or P rostate C ancer (1999) (1)
American Society of Clinical Oncology/College ofAmerican Pathologists guideline recommendations forimmunohistochemical testing of estrogen andprogesterone receptors in breast cancer (2010) (1)
Pathology issues in the evaluation of prostate cancer (1996) (1)
Histological Trends and the Index Lesion in Localized Prostate Cancer (2011) (1)
Abstract 5165: Fatty acid diversification in prostate cancer progression (2012) (1)
Sporadic clear cell papillary cystadenoma of the epididymis can show somatic mutation of the VHL gene (1996) (1)
1661: Comparison of %FPSA, %BPSA, [-2]PPSA/FPSA, and [- 2]PPSA/BPSA for Prostate Cancer Detection in men With total Serum PSA Concentrations Between 4 and 10 NG/NL (2004) (1)
pT3N0 PROSTATE CANCER PATIENTS WITH RT-PCR-hK2-L-POSITIVE LYMPH NODES ARE AT HIGHER RISK FOR RECURRENCE (1999) (1)
MP65-05 TRANSURETHRAL BIOPSY OF THE PROSTATIC URETHRA FREQUENTLY DETECTS CARCINOMA IN-SITU AND INVASIVE UROTHELIAL CARCINOMA ARISING FROM THE PROSTATIC URETHRA AND DUCTS/ACINI (2014) (0)
Personalized multimodality therapy with immune checkpoint inhibitors, chemotherapy, and targeted treatment (ICTriplex) in advanced/refractory cancer. (2022) (0)
The pathologist as expert witness. (1986) (0)
1031: Total Surgical Experience, Regardless of Surgical Approach, Predicts Positive Surgical Margins for Skilled Open Surgeons Performing Robotic-Assisted Laparoscopic Radical Retropubic Prostatectomy (2005) (0)
Pathologic Basis for Focal Therapy: Understanding Cancer Grade, Volume, and Spatial Location (2013) (0)
In response to Dr. Macias (2004) (0)
Pathologic Rationale for Focal Therapy of Prostate Cancer: Elucidating Tumor Characteristics and Biology (2017) (0)
471: Biopsy Gleason 8-10 Prostate Cancer: Incidence of Downgrading and Outcome (2005) (0)
ORIGIN AND DEVELOPMENT OF AMERICAN SURGICAL PATHOLOGY. (2020) (0)
Features of burnout amongst pathologists: A reassessment (2022) (0)
European Society of Pathology and International Academy of Pathology combined symposium (2004) (0)
Duffy Antigen/Receptor for Chemokines (DARC): Is There a Role in Prostate Cancer?. (2005) (0)
Reply by Authors. (2020) (0)
COMPLEX IN-VITRO THREE-DIMENSIONAL TUMOR ARCHITECTURE WITH MULTIPLE CELL TYPES (2009) (0)
PATHOGENESIS OF INTRALUMINAL PROSTATIC CRYSTALLOIDS. AUTHORS' REPLY (1999) (0)
Can Sural Nerve Grafting Restore Potency in Humans ? (2001) (0)
59: Thrombospondin-1, Through Angiocidin, Up-Regulates Gelatinase Expression in Colon Cancer Cells (2009) (0)
First International Workshop on Focal Therapy and Imaging of Prostate Cancer (2018) (0)
Lesions of Ductal Morphology ¿ Reply (2008) (0)
Computational discovery of non-mutational tumor-restricted antigens reveals evidence of immunoediting in head and neck squamous cell carcinoma. (2020) (0)
Editorial Comment. (2017) (0)
Residual Tumor After Transurethral Resection of the Prostate: Features of Incidentally Found Prostate Cancer in Transurethral and Radical Prostatectomy Specimens (1991) (0)
Fine-needle aspiration biopsy of thyroid nodules. (1982) (0)
Differential E xpression o f N uclear R etinoid R eceptors i n Normal a nd M alignant P rostates (2000) (0)
420: Axonogenesis is Present in Preneoplastic Lesions such as High Grade Prostatic Intraepithelial Neoplasia (2006) (0)
Minimal Diagnostic Criteria for Prostatic Adenocarcinoma in Needle Biopsies (2000) (0)
Effects of temperature on the stiffness of breast tissues (2000) (0)
Ductal adenocarcinoma of the prostate. (2011) (0)
Abstracts from the First International Workshop on Focal Therapy and Imaging of Prostate Cancer, February 21-22, 2008, the Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, North Carolina (2008) (0)
PATHOLOGIC FEATURES AND FOLLOW UP OF PROSTATE CANCER PATIENTS WITH INITIAL SEXTANT BIOPSY POSITIVE VS THOSE WITH AT LEAST ONE PREVIOUSLY NEGATIVE SEXTANT BIOPSY (1999) (0)
461: Increasing the Predictive Ability of Clinico-pathologic Markers for Prostate Cancer using Biomarkers Derived from High-Throughput Tissue Micorarray Studies in a Large Retrospective Cohort: A Stratification Strategy (2005) (0)
Lesions of Ductal Morphology in the Prostate. Authors' reply (2008) (0)
214: Pim-2 Silencing Promotes Apoptosis in Perineural Invasion of Prostate Cancer in Vitro (2005) (0)
Top Game Changers in Pathology (0)
Prognostic indicators for disease progression following radical prostatectomy (2006) (0)
Lesions of ductal morphology in the prostate - Reply (2008) (0)
Prostate Cancer: Screening, Surveillance, Prognostic Algorithms and Independent Pathologic Predictive Parameters (2014) (0)
796: SEMA4F Overexpression in Perineural Invasion in Vitro Model of Prostate Cancer and Its Functional Involvement in Axonogenesis (2006) (0)
Discovery of a genomic classifier for predicting clinically aggressive luminal bladder tumors with higher rates of pathological upstaging (2020) (0)
REDUCTION IN LYSYL OXIDASE EXPRESSION IS AN INDEPENDENT PREDITOR OF RECURRENCE FOLLOWING RADICAL PROSTATECTOMY (1999) (0)
The Pathologic Features and DNA Ploidy Value of Prostate Cancers Detectable by Sonography and by Palpation : ワークショップII : 泌尿器科領域における新しい物理的治療法 : 第57回東部総会 (1993) (0)
EARLY POSTOPERATIVE ULTRASENSITIVE PSA LEVEL PREDICTS RECURRENCE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY (2008) (0)
Possible Role of Monocyte Suppression (1982) (0)
462: Increased PIM-2 is an Adverse Indicator of Aggressive Disease and is Associated with Perineural Invasion of Prostate Cancer (2005) (0)
PROGNOSTIC SIGNIFICANCE OF POSITrVE SURGICAL MARGINS IN RADICAL PROSTATECTOMY SPECIMENS (1995) (0)
Preoperative P lasma L evels o f T ransforming G rowth F actor Beta 1 (TGF- b 1 ) S trongly P redict P rogression i n P atients Undergoing R adical P rostatectomy (2001) (0)
Quantification of total and high-grade cancer in biopsy cores improves the prediction of PSA recurrence after Radical Prostatectomy (RP) (2002) (0)
Comment on: Focal Therapy for Localized Prostate Cancer : A Critical Appraisal of Rationale and Modalities. Authors' reply (2008) (0)
1427: Circulating Levels of Plasminogen Activation Inhibitor-1 Improve the Accuracy of Pre- and Post-Operative Nomograms for Prediction of Prostate Cancer Recurrence after Radical Prostatectomy (2007) (0)
954: Serum BPSA Predicts Prostate Volume Despite the Presence of Clinically Localized Prostate Cancer in Men Undergoing Prostate Biopsy (2005) (0)
Detailed assessment of the radial distance of extracapsular extension (ECE) from 712 radical prostatectomy specimens: implications for treatment planning margins for brachytherapy and conformal radiotherapy (2002) (0)
908 ASSOCIATION OF BLOOD LEVELS OF UROKINASE PLASMINOGEN ACTIVATOR AND ITS SOLUBLE RECEPTOR WITH PROSTATE CANCER PRESENCE, INVASION, PROGRESSION, AND METASTASIS (2007) (0)
Detection o f C linically S ignificant, O ccult P rostate C ancer Metastases i n L ymph N odes U sing a S plice V ariant-Specific RT-PCR A ssay f or H uman G landular K allikrein (2003) (0)
Biopsy Interpretation of the Prostate (2009) (0)
Prostate Cancer in Lymph Nodes Transcription-PCR for the Detection of Micrometastatic Comparison of Immunohistochemistry with Reverse Updated Version (2003) (0)
247: Three Dimensional Reconstruction of Nervature in Prostate: Confirming Cancer Related Axonogenesis (2006) (0)
409: A Systems Pathology Approach to Predict Survival after Radical Prostatectomy (2005) (0)
Personalized multimodality therapy with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT) in advanced refractory cancer. (2019) (0)
Pathogenesis of Intraluminal Prostatic Crystalloids (1999) (0)
639: Predictors of Prostate Cancer Detection Using an Extended Biopsy Regimen in Patients with a Total PSA Between 2.5 and 4.0NG/ML (2004) (0)
923. Combining In Situ Gene Therapy with Radiotherapy and Hormonal Therapy in the Treatment of Stage D1 Prostate Cancer (2006) (0)
Personalized multimodality therapy (ICT) with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT), in advanced/refractory cancer. (2019) (0)
805: High-Level Cyclin D1 is Associated with High Gleason Grade and Predicts Worse Biochemical-Free Survival in Prostate Cancer (2006) (0)
58: Angiocidin siRNA Inhibits Colon Cancer Growth in Vivo (2009) (0)
458: Loss of Tumor Suppressor Gene Expression in Normal Prostate Tissue Adjacent to Cancer (2005) (0)
CTV margins in prostate cancer irradiation. In regard to TEH et AL: IMRT for prostate cancer: Defining target volume based on correlated pathologic volume of disease. Authors' reply (2004) (0)
Second opinions in pathology. (2010) (0)
The role of CAP in standardisation of pathology practice, including our laboratory accreditation program, predictive markers (HER2, ER, PR) and pathology report standardisation (2009) (0)
MP26-15 MOLECULAR SUBTYPING REVEALS LUMINAL BLADDER TUMORS HAVE LOWER RATES OF PATHOLOGICAL UPSTAGING AT RADICAL CYSTECTOMY (2019) (0)
Systemic T-cell activation following in situ gene therapy in prostate cancer patients (2002) (0)
Advances in Brief Age-related Radical-induced DNA Damage Is Linked to Prostate Cancer 1 (2001) (0)
Prediction o f R esponse t o S alvage R adiation T herapy i n Patients W ith P rostrate C ancer R ecurrence A fter R adical Prostatectomy (2001) (0)
902 Transurethral biopsy of the prostatic urethra frequently detects carcinoma in-situ and invasive urothelial carcinoma arising from the prostatic urethra and ducts/acini (2014) (0)
Serum caveolin-1 discriminate between BPH and prostate cancer and is a prognostic marker for prostate cancer progression (2003) (0)
Long-term Outcome of a Phase II Trial Combining in Situ Gene Therapy and Intensity Modulated Radiotherapy With or Without Hormonal Therapy for Prostate Cancer (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thomas M. Wheeler?

Thomas M. Wheeler is affiliated with the following schools:

Thomas M. Wheeler's Academic­Influence.com Rankings

Thomas M. Wheeler's Degrees

Why Is Thomas M. Wheeler Influential?

Thomas M. Wheeler's Published Works

Published Works

What Schools Are Affiliated With Thomas M. Wheeler?

Thomas M. Wheeler's AcademicInfluence.com Rankings